Physician profile
Samir Ved Kubba
NPI 1164405882
$27,513.89
in general payments reported to CMS, 2019-2025
95 companies · $5,076 in 2025
The $5,076 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,891 · 2020: $2,935 · 2021: $3,286 · 2022: $3,674 · 2023: $5,054 · 2024: $3,597 · 2025: $5,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,388 · Education: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,639.11 |
| Consulting Fee | $1,387.50 |
| Education | $700.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,322.47 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $2,088.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,800.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,530.28 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $1,227.97 | 2019-2025 | Opdivo, Reblozyl |
| Celgene Corporation | $892.21 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Genzyme Corporation | $891.38 | 2019-2025 | |
| Astellas Pharma US INC | $817.77 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Pfizer INC. | $798.10 | 2019-2025 | |
| Incyte Corporation | $761.44 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Gilead Sciences, INC. | $716.04 | 2019-2025 | Trodelvy |
| Seagen INC. | $620.40 | 2019-2025 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $615.37 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Beigene USA, INC. | $571.32 | 2020-2025 | Brukinsa |
| Genentech USA, INC. | $562.49 | 2019-2025 | Polivy, Venclexta, Phesgo |
Show all 95 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Kubba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.